A team of investigators from Texas Heart Institute, Texas Children’s Hospital and Baylor College of Medicine uncovered new insights into the mechanisms underlying the progression of congenital heart disease (CHD) ― a spectrum of heart defects that develop before birth and remain the leading cause of childhood death.
Two nationally recognized experts in cloning and stem cell science from the University of Houston are taking the first step toward limiting the consequences of chronic inflammation in cystic fibrosis (CF) by identifying the source of this persistent and enigmatic inflammation in CF lungs.
UNC-Chapel Hill, Princeton, and Boston Children’s Hospital researchers show how three transcription factors inside the embryonic heart recruit the protein subunit CHD4 for their role known roles in heart health and disease.
Article title: Chronic perinatal hypoxia delays cardiac maturation in a mouse model for cyanotic congenital heart disease Authors: Jennifer Romanowicz, Devon Guerrelli, Zaenab Dhari, Colm Mulvany, Marissa Reilly, Luther Swift, Nimisha Vasandani, Manelle Ramadan, Linda Leatherbury, Nobuyuki Ishibashi, Nikki Gillum…
In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of hypertension — high blood pressure — within a few months or years after surgery.
In recognition of its expertise in treating adults with congenital heart disease (ACHD), the Mount Sinai Adult Congenital Heart Disease Center has been accredited by the Adult Congenital Heart Association (ACHA) as a Comprehensive Care Center.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.
With global temperatures on the rise, medical investigators are taking a deeper look at the potential link between climate change and the rise of congenital heart disease-the most common birth defect, affecting some 40,000 children born every year in the U.S.
While transcatheter aortic valve replacement (TAVR) continues to expand its pool of eligible patients, open heart surgery—resulting in excellent patient survival and fewer strokes when compared to TAVR—is the best option for young and middle-aged adults with aortic valve disease—at least for now.
The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity in adolescent patients with severe, congenital single-ventricle heart defects. A study leader says the physiologic benefits represent a milestone in pediatric cardiology.